Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers
- PMID: 22710446
- DOI: 10.1016/j.clim.2012.05.006
Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers
Abstract
Noroviruses are the most frequent cause of acute gastroenteritis in humans of all ages. No vaccines are currently available. An intranasally delivered Norwalk (NV) virus-like particle (VLP) vaccine was recently shown to be well tolerated, immunogenic and to protect against infection in Phase 1 studies. Here, we examined B memory (B(M)) responses in volunteers who received the highest dosage levels of the NV-VLP vaccine (50 μg and 100 μg). We measured the frequency of NV-specific IgG and IgA-secreting B(M) cells in peripheral blood and the level of antibodies produced by these cells in culture. All subjects immunized with 100 μg of the NV-VLP vaccine and 90% of those who received 50 μg had significant IgA or IgG B(M) responses. The B(M) cell frequencies correlated with serum antibody levels and mucosally-primed antibody-secreting cell responses. This is the first demonstration of dose-dependent, functional B(M) responses in humans immunized intranasally with a NV-VLP vaccine.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine.Vaccine. 2015 Jan 15;33(4):568-76. doi: 10.1016/j.vaccine.2014.09.073. Epub 2014 Nov 22. Vaccine. 2015. PMID: 25444793 Clinical Trial.
-
Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.J Infect Dis. 2010 Dec 1;202(11):1649-58. doi: 10.1086/657087. Epub 2010 Oct 27. J Infect Dis. 2010. PMID: 20979455 Free PMC article. Clinical Trial.
-
Mucosal and Cellular Immune Responses to Norwalk Virus.J Infect Dis. 2015 Aug 1;212(3):397-405. doi: 10.1093/infdis/jiv053. Epub 2015 Jan 29. J Infect Dis. 2015. PMID: 25635121 Free PMC article.
-
Norwalk virus-like particles as vaccines.Expert Rev Vaccines. 2010 Mar;9(3):299-307. doi: 10.1586/erv.09.163. Expert Rev Vaccines. 2010. PMID: 20218858 Free PMC article. Review.
-
The Density Code for the Development of a Vaccine?J Pharm Sci. 2016 Nov;105(11):3223-3232. doi: 10.1016/j.xphs.2016.07.020. Epub 2016 Sep 17. J Pharm Sci. 2016. PMID: 27649885 Free PMC article. Review.
Cited by
-
Insights from natural infection-derived immunity to cholera instruct vaccine efforts.Clin Vaccine Immunol. 2012 Nov;19(11):1707-11. doi: 10.1128/CVI.00543-12. Epub 2012 Sep 19. Clin Vaccine Immunol. 2012. PMID: 22993412 Free PMC article. No abstract available.
-
Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae.Hum Vaccin Immunother. 2015;11(3):584-600. doi: 10.1080/21645515.2015.1011019. Hum Vaccin Immunother. 2015. PMID: 25715048 Free PMC article. Review.
-
Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives.Future Virol. 2015;10(7):899-913. doi: 10.2217/fvl.15.57. Future Virol. 2015. PMID: 26568768 Free PMC article.
-
Intranasal immunization with dry powder vaccines.Eur J Pharm Biopharm. 2018 Jan;122:167-175. doi: 10.1016/j.ejpb.2017.11.001. Epub 2017 Nov 6. Eur J Pharm Biopharm. 2018. PMID: 29122735 Free PMC article. Review.
-
Vaccines against gastroenteritis, current progress and challenges.Gut Microbes. 2020 Nov 1;11(6):1486-1517. doi: 10.1080/19490976.2020.1770666. Epub 2020 Jun 18. Gut Microbes. 2020. PMID: 32552414 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous